



(51) **International Patent Classification:**
C07K 16/28 (2006.01) A61P 35/00 (2006.01)
A61K 39/00 (2006.01)

maceuticals LP, 1800 Concord Pike, Wilmington, Delaware 19803 (US).

(21) **International Application Number:**
PCT/EP2021/062695

(74) **Agent:** MACLEAN, Martin Robert; Mathys & Squire, The Shard, 32 London Bridge Street, London SE1 9SG (GB).

(22) **International Filing Date:**
12 May 2021 (12.05.2021)

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
63/023,554 12 May 2020 (12.05.2020) US

(71) **Applicant:** ASTRAZENECA AB [SE/SE]; 151 85, Södertälje (SE).

(72) **Inventors:** KURLAND, John; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, Delaware 19803 (US). NEGRO, Alejandra; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, Delaware 19803 (US). CHANG, Shao-Chun; c/o AstraZeneca Phar-

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) **Title:** METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES




FIGURE 1

(57) **Abstract:** The disclosure relates to methods, compositions, and combinations for the treatment of cancer. Specifically, the disclosure relates to methods comprising administering to a subject in need thereof at least one of an anti-CTLA-4 antibody or an antigen-binding fragment and an anti-PD-L1 antibody or an antigen-binding fragment thereof. The disclosure also relates to combinations comprising at least one of an anti-CTLA-4 antibody or an antigen-binding fragment and an anti-PD-L1 antibody or an antigen-binding fragment thereof.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*